Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.03) by 366.67 percent. The company reported quarterly sales of $85.800 million which beat the analyst consensus estimate of $79.842 million by 7.46 percent. This is a 39.53 percent increase over sales of $61.493 million the same period last year.